Jlroz 15 Orally Disintegrating Tablet contains Lansoprazole 15mg, a proton pump inhibitor used to reduce gastric acid secretion. It is indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, Zollinger-Ellison syndrome, and other conditions associated with excessive stomach acid production. The orally disintegrating formulation facilitates rapid disintegration in the mouth without the need for water, improving patient compliance, especially in individuals with swallowing difficulties. Lansoprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing the final step of acid production. This results in decreased gastric acidity, promoting healing of acid-related mucosal damage and relief of symptoms such as heartburn and acid regurgitation. Jlroz 15 is typically administered once daily before meals, with dosage adjustments based on clinical response and specific indications. It is generally well tolerated; however, potential adverse effects include headache, abdominal pain, nausea, and diarrhea. Long-term use may be associated with risks such as vitamin B12 deficiency and increased susceptibility to gastrointestinal infections. Patients should consult their healthcare provider before initiating therapy and report any unusual symptoms promptly.